254 related articles for article (PubMed ID: 22595948)
21. PAX2(-)/PAX8(-)/inhibin A(+) immunoprofile in hemangioblastoma: A helpful combination in the differential diagnosis with metastatic clear cell renal cell carcinoma to the central nervous system.
Carney EM; Banerjee P; Ellis CL; Albadine R; Sharma R; Chaux AM; Burger PC; Netto GJ
Am J Surg Pathol; 2011 Feb; 35(2):262-7. PubMed ID: 21263247
[TBL] [Abstract][Full Text] [Related]
22. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.
Knoepp SM; Kunju LP; Roh MH
Diagn Cytopathol; 2012 Aug; 40(8):667-72. PubMed ID: 22807381
[TBL] [Abstract][Full Text] [Related]
23. SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.
Zhang X; Yao J; Niu N; Li X; Liu Y; Huo L; Euscher ED; Wang H; Bell D; Sood AK; Wang G; Lawson BC; Ramalingam P; Malpica A; Sahin AA; Ding Q; Liu J
Mod Pathol; 2023 Feb; 36(2):100001. PubMed ID: 36853778
[TBL] [Abstract][Full Text] [Related]
24. [Origin of ovarian epithelial inclusions and its relationship with the development of low-grade serous carcinoma].
Xiang L; Li J; Wang LJ; Zheng WX; Kong BH
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):729-35. PubMed ID: 22321344
[TBL] [Abstract][Full Text] [Related]
25. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
26. Pax8: a marker for carcinoma of Müllerian origin in serous effusions.
Tong GX; Devaraj K; Hamele-Bena D; Yu WM; Turk A; Chen X; Wright JD; Greenebaum E
Diagn Cytopathol; 2011 Aug; 39(8):567-74. PubMed ID: 20607683
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of P-glycoprotein on frozen and paraffin-embedded tissue sections of normal and malignant tissues.
Bittl A; Nap M; Jäger W; Cornillie F; Lang N
Anticancer Res; 1995; 15(3):1007-14. PubMed ID: 7645919
[TBL] [Abstract][Full Text] [Related]
28. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.
Hu A; Li H; Zhang L; Ren C; Wang Y; Liu Y; Liu C
J Clin Pathol; 2015 Jul; 68(7):522-8. PubMed ID: 25827135
[TBL] [Abstract][Full Text] [Related]
29. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck.
Bishop JA; Sharma R; Westra WH
Hum Pathol; 2011 Dec; 42(12):1873-7. PubMed ID: 21663937
[TBL] [Abstract][Full Text] [Related]
30. Pax8 as a useful adjunct marker to differentiate pancreatic serous cystadenoma from clear cell renal cell carcinoma in both cytologic and surgical specimens.
Chi Z; Xu J; Karamchandani DM; Peng L
Diagn Pathol; 2023 Apr; 18(1):54. PubMed ID: 37098593
[TBL] [Abstract][Full Text] [Related]
31. p63, CK7, PAX8 and INI-1: an optimal immunohistochemical panel to distinguish poorly differentiated urothelial cell carcinoma from high-grade tumours of the renal collecting system.
Carvalho JC; Thomas DG; McHugh JB; Shah RB; Kunju LP
Histopathology; 2012 Mar; 60(4):597-608. PubMed ID: 22260386
[TBL] [Abstract][Full Text] [Related]
32. Characterization and applications of a newly developed rabbit monoclonal antibody to cytokeratin 7 (CK7) for immunohistochemistry.
Qi W; Chu J; Zhou D; Tacha D
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):233-8. PubMed ID: 19098679
[TBL] [Abstract][Full Text] [Related]
33. The utility of PAX-2 and renal cell carcinoma marker immunohistochemistry in distinguishing papillary renal cell carcinoma from nonrenal cell neoplasms with papillary features.
Sharma SG; Gokden M; McKenney JK; Phan DC; Cox RM; Kelly T; Gokden N
Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):494-8. PubMed ID: 21102195
[TBL] [Abstract][Full Text] [Related]
34. Expression of renal cell carcinoma antigen (RCC) in renal epithelial and nonrenal tumors: diagnostic Implications.
Bakshi N; Kunju LP; Giordano T; Shah RB
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):310-5. PubMed ID: 17721277
[TBL] [Abstract][Full Text] [Related]
35. PAX8 (+)/p63 (-) immunostaining pattern in renal collecting duct carcinoma (CDC): a useful immunoprofile in the differential diagnosis of CDC versus urothelial carcinoma of upper urinary tract.
Albadine R; Schultz L; Illei P; Ertoy D; Hicks J; Sharma R; Epstein JI; Netto GJ
Am J Surg Pathol; 2010 Jul; 34(7):965-9. PubMed ID: 20463571
[TBL] [Abstract][Full Text] [Related]
36. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.
Bishop JA; Sharma R; Illei PB
Hum Pathol; 2010 Jan; 41(1):20-5. PubMed ID: 19740516
[TBL] [Abstract][Full Text] [Related]
37. PAX-8 expression in primary and metastatic Merkel cell carcinoma: an immunohistochemical analysis.
Sangoi AR; Cassarino DS
Am J Dermatopathol; 2013 Jun; 35(4):448-51. PubMed ID: 23612030
[TBL] [Abstract][Full Text] [Related]
38. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium.
Iwamoto M; Nakatani Y; Fugo K; Kishimoto T; Kiyokawa T
Hum Pathol; 2015 Jul; 46(7):957-62. PubMed ID: 25971546
[TBL] [Abstract][Full Text] [Related]
39. Utility of monoclonal PAX8 antibody for distinguishing intrathyroid thymic carcinoma from follicular cell-derived thyroid carcinoma.
Suzuki A; Hirokawa M; Takada N; Higuchi M; Tanaka A; Hayashi T; Kuma S; Miyauchi A
Endocr J; 2018 Dec; 65(12):1171-1175. PubMed ID: 30210064
[TBL] [Abstract][Full Text] [Related]
40. NY-BR-1 and PAX8 immunoreactivity in breast, gynecologic tract, and other CK7+ carcinomas: potential use for determining site of origin.
Woodard AH; Yu J; Dabbs DJ; Beriwal S; Florea AV; Elishaev E; Davison JM; Krasinskas AM; Bhargava R
Am J Clin Pathol; 2011 Sep; 136(3):428-35. PubMed ID: 21846919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
